TITAN PHARMACEUTICALS INC
TTNPHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | $184,000 | $557,000 | $1.5M | $4.8M | $2.6M |
| Operating income | −$4.6M | −$7.3M | −$10.2M | −$9.4M | −$7.4M | −$7.9M |
| Net income | −$4.7M | −$5.6M | −$10.2M | −$8.8M | −$18.2M | −$16.5M |
| Total assets | $2.9M | $8.1M | $4.1M | $8.0M | $8.1M | $9.5M |
| Total liabilities | $483,000 | $1.4M | $2.7M | $2.9M | $4.6M | $8.1M |
| Equity | $2.4M | $6.6M | $1.4M | $5.1M | $3.5M | $1.4M |
| EPS (diluted) | $-5.23 | $-7.41 | $-15.19 | — | — | $-0.34 |
| Shares out. | 914,234 | 15.0M | 12.0M | 9.9M | 93.5M | 13.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −192.9%
- Return on assets
- −161.0%
- Return on capital (ROCE)
- −186.8%
- Liabilities / assets
- 16.5%
- Debt / equity
- 0.20×
- Book value / share
- $2.67
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -441.95distress
- Accruals / assets
- −28.3%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Sep 30, 2025 | 25,330 | 1.9 | -28.4% |
| Sep 15, 2025 | 35,404 | 1.6 | -39.7% |
| Aug 29, 2025 | 58,677 | 1.0 | +116.5% |
| Aug 15, 2025 | 27,105 | 1.6 | -22.0% |
| Jul 31, 2025 | 34,764 | 1.0 | +305.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Modified shareholder rights · Change in control · Director / officer changeOct 1, 2025
- Shareholder voteAug 26, 2025
- Entered a material agreement · Unregistered equity saleJun 27, 2025
- Shareholder voteJun 18, 2025
- Other material eventJun 3, 2025
- Delisting / listing-standard noticeJun 2, 2025
- Other material eventApr 22, 2025
- Entered a material agreement · Delisting / listing-standard notice · Unregistered equity sale · Director / officer changeApr 1, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.